2008, Number 2
<< Back Next >>
Dermatología Cosmética, Médica y Quirúrgica 2008; 6 (2)
Drug-Induced Delayed Multiorgan Hypersensitivity Syndrome or DIDMOHS induced by carbamazepine
Poletti ED, García RC, Márquez DF
Language: Spanish
References: 28
Page: 99-105
PDF size: 2279.03 Kb.
ABSTRACT
62 year old feminine patient, who was hospitalized for presenting deterioration of conscience, fever, with
generalized maculopapular exanthem, which later evolved to erythroderma and jaundice. She also had
lymphadenopathy and laboratory data suggested multiorgan dysfunction (hepatic enzymes, creatinine,
eosinophilia and atypical lymphocytosis). The most relevant background data was the use of carbamazepine since
two months before. “Drug-induced delayed multiorgan hypersensitivity syndrome” (didmohs) was corroborated.
Her therapeutical response was immediate after the administration of intravenous pulses of methylprednisolone,
with functional cutaneous recovery and all the laboratory parameters which were modified.
REFERENCES
Callen JP, Jorizzo J, Bolognia J, Piette WW y Zone JJ, Dermato logical signs of internal medicine, 3a ed., Saunders, Philadelphia, 2003; 343-351. 104 Dermatología Cosmética, Médica y Quirúrgica Volumen 6 / Número 2 / abril-junio 2008 U R G E N T I A C U T I S
Sontheimer R y Houpt K, DIDMOHS: a proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome, Arch Dermatol 1998; 134: 874-875.
Bocquet H, Bagot M y Roujeau JC, DIDMOHS: a proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome (in reply), Arch Dermatol 1998;134: 875.
Ben-Ari Maoz K y Brenner S, Drug Rash with Eosinophilia and Systemic Symptoms Syndrome: Sex and the Causative Agent, SKINmed 2007; 6 (6): 271-273.
Karduan SH, Sidorof FL, Valeyrie-Allanore S y Rojeau JC, Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?, Br J Dermatol 2007; 156: 575-612.
Sullivan JR y Shear NH, The drug hypersensitivity syndrome: what is the pathogenesis?, Arch Dermatol 2001;137: 357-364.
Revuz J, New advances in severe adverse drug reactions, Dermatol Clin 2001; 19: 697-708.
Pérez A, Calvo E, Lozano C y Espinós D, Síndrome de hipersensibilidad retardada a fármacos, Rev Clin Esp 2002; 202:339-346.
Bocquet H, Bagot y Roujeau JC, Drug-induced pseudolymphoma and drug induced hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS), Semin Cutan Med Surg 1996;15: 250-257.
10.Wolverton SE, Comprehensive dermatologic drug therapy, 2a ed., Saun ders Elsevier, Philadelphia, 2007; 978-988.
Wolf K, Goldsmith LA, Katz Gilchrest SI, Paller AS y Leffell DJ, Fitzpatrick´s Dermatology in general medicine, 7a ed., McGraw Hill Medical, Nueva York, 2008; 355-361.
Bolognia JL, Jorizzo JL, Rapini RP, et al., Dermatology, 2a ed., Mosby- Elsevier, St. Louis, 2008; 310-311.
Gennis M, Vemuri R, Burns R, Hill J, Miller M y Spielberg S, Familial occurrence of hypersensitivity to phenytoin, Am J Med 1991; 91: 631-635.
Vittorio C y Muglia J, Anticonvulsant hypersensitivity syndrome, Arch Intern Med 1995; 155: 2285-2290.
Descamps V y Valance A, Association of human herpes virus 6 infection with drug reaction with eosinophilia and systemic symptoms, Arc Dermatol 2001; 137: 301-304.
Tohyama M, Yahata Y, Yasukawa M, et al., Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpes 6, Arch Dermatol 1998; 134: 1113–1117.
Suzuki Y, Inagi T, Aono et al., Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome, Arch Dermatol 1998; 134: 1108-1112.
Kano Y, Inaoka M y Shiohara T, Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia, Arch Dermatol 2004; 140: 183-188.
Tamagawa-Mineoka R, Katoh N, Nara T, Nishimura Y, Yama moto S y Kishimoto S, DRESS syndrome caused by teicoplanin and vancomycin, associated with reactivation of human herpesvirus-6, Int Jou Dermatol 2007, 46: 654-655.
20.Shiohara T, y KanoY, Are viral infections responsible for the development of drug-induced hypersensitivity syndrome as well as graft-versus-host diseases?, Dermatology 2005; 210: 259-260.
Callot V, Roujeau JC, Bagot M, Wechsler J, Chosidow O, Souteyrand P, et al., Drug-induced pseudolymphoma and hypersensitivity syndrome, Arch Dermatol 1996; 132: 1315-1321.
Durán M y Danés I, Síndrome de hipersensibilidad por antiepilépticos, Med Clin 2001; 115: 155-156.
Tennis P y Stern R, Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study, Neurology 1997; 49: 542-546. 24.Tas S y Simonart T, Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update, Dermatology. 2003; 206: 353-356.
Chang D y Shear N, Cutaneous reactions to anticonvulsivants, Semin Neurol 1992; 12: 329-337.
Pinós T, Ramoneda S, Palacín A y Quesada A, Hepatitis tóxica por difenilhidantoínas: aportación y estudio de un nuevo caso y revisión de la literatura, Gastroenterol Hepatol 1987; 9: 458-461.
Angle P, Thomas P, Chiu B y Freedman J, Bronchiolitis obliterans with organizing pneumonia and cold agglutinin disease associated with phenytoin hypersensitivity syndrome, Chest 1997; 112: 1697-1699.
Lebowl MG, Heymann WR, Berth-Jonez J y Coulson I, Treatment of skin disease, comprehensive therapeutic strategies, 2a ed., Mosby Elsevier, St. Louis, 2006, 178-179.
Litt JZ, Drug eruption reference manual, 14a ed., Informa Healthcare, Nueva York, 2008, 589-643.